NCT01127620View on ClinicalTrials.gov

Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension

PHASE3CompletedINTERVENTIONAL
Enrollment

650

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

November 30, 2006

Conditions
Perennial Allergic Rhinitis
Interventions
DRUG

Bilastine

20 mg encapsulated tablets

DRUG

Cetirizine

10 mg encapsulated tablets

DRUG

Placebo

encapsulated tablets

Sponsors

Lead Sponsor

Faes Farma, S.A.
All Listed Sponsors
lead

Faes Farma, S.A.

INDUSTRY

NCT01127620 - Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension | Biotech Hunter | Biotech Hunter